Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 3;28(6):862-869.
doi: 10.1093/ibd/izab192.

What Is a Flare? The Manitoba Living With IBD Study

Kelcie Witges  1 , Kathryn Sexton  1 , Lesley A Graff  1   2 , Laura E Targownik  1   3 , Lisa M Lix  1   4 , Clove Haviva  1 , James Stone  1   5 , Leigh Anne Shafer  1   5 , Kathy Vagianos  1   6 , Charles N Bernstein  1   5
Affiliations

What Is a Flare? The Manitoba Living With IBD Study

Kelcie Witges et al. Inflamm Bowel Dis. .

Abstract

Background: Flare is a poorly defined term used by patients and clinicians to indicate inflammatory bowel disease (IBD) status. This study aimed to evaluate the validity of a single-item 7-point flare indicator relative to other measures of disease flare.

Methods: The longitudinal Manitoba Living with IBD Study followed persons with IBD for 1 year; they completed biweekly online surveys and provided 3 stool samples. Disease flare on a single-item flare indicator with 7 possible responses developed for the study was defined by report of symptoms as "moderately" or "much" worse. The flare indicator was evaluated against 5 measures of disease activity: fecal calprotectin score (FCAL), a 2-point disease status indicator, a 4-point flare certainty indicator, the IBD Symptom Index short form (SIBDSI), and the short form IBD Questionnaire (SIBDQ). Participants in a flare, based on the 7-point measure, were matched to a nonflaring participant, and a stool sample was collected.

Results: Of the 155 IBD participants, almost half (n = 74) experienced a flare. Of those who flared, 97.0% endorsed active IBD on the 2-point indicator (controls 42.5%; P < .001); 91.9% endorsed active IBD on the 4-point certainty indicator (controls 32.9%; P < .001); 90.5% endorsed active disease on the SIBDSI (controls 34.2%; P < .001); and 48.5% had an elevated FCAL (controls 34.3%; P < .05). The mean SIBDQ was lower for the flare group compared with controls (43.9 [SD 11.1] vs 58.3 [SD 8.5]; P < .001), indicating worse disease.

Conclusions: The 7-point flare indicator robustly identified symptomatic flares. This patient self-report indicator reflected meaningful changes in more complex clinical indices and had only weak concordance with the presence of inflammation.

Keywords: IBD symptom inventory; disease activity; disease flare; fecal calprotectin; symptoms.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of flare cases and matched control cases with active disease as defined by clinical and patient report measures.
See this image and copyright information in PMC

References

    1. Liverani E, Scaioli E, Digby RJ, et al. . How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016;22:1017–1033. - PMC - PubMed
    1. Bernstein CN, Singh S, Graff LA, et al. . A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105:1994–2002. - PubMed
    1. Matsuoka K, Kobayashi T, Ueno F, et al. . Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–353. - PMC - PubMed
    1. Falvey JD, Hoskin T, Meijer B, et al. . Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824–831. - PubMed
    1. Docherty MJ, Jones RC 3rd, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7:592–601. - PMC - PubMed

Publication types

Substances

Grants and funding